A randomized, double-blind, placebo-cont
β
Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh
π
Article
π
2011
π
John Wiley and Sons
π
English
β 446 KB
π 2 views
## Abstract Safinamide is an Ξ±βaminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an addβon to dopamine agonist (DA) therapy in earlyβstage PD. In this 24βweek, doubleβblind study, patients with early PD receiving a stable dose of a single DA were randomized to